Royalty Pharma plc (RPRX)
NASDAQ
62.07
+0.74 (+1.21%)
Real-time Data
01:30 PM
Day's Range
60.8862.45
52 wk Range
34.0862.45
Financial Statements - RPRX - Royalty Pharma plc
Revenue
2.37B▲ 5.1%
Net Income
1.32B▼ 0.5%Net Margin 55.7%
EBITDA
1.61B▲ 17.8%
Free Cash Flow
2.48B▼ 10.1%
Income Statement
| Period Ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
|---|---|---|---|---|---|---|
| Sales | 2.37B | 2.26B | 2.35B | 2.23B | 2.28B | 2.12B |
| Cost of Goods | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - |
 Operating Expense | - | - | - | - | - | - |
| Operating Income | 1.55B | 1.29B | 1.49B | 922.89M | 1.43B | 1.66B |
| Non-Operating Interest | - | - | - | - | - | - |
| Other Income Expense | 38.74M | 216.53M | 322.83M | -583.20M | -76.90M | 170.18M |
| Pre Tax Income | 1.32B | 1.33B | 1.70B | 230.06M | 1.24B | 1.70B |
| Income Tax | 0 | 0 | 0 | 0 | 0 | 0 |
| Net Income | 1.32B | 1.33B | 1.70B | 230.06M | 1.24B | 1.70B |
| EPS Basic | 1.79 | 1.926074 | 2.54 | 0.1 | 1.49 | 2.512013 |
| EPS Diluted | 1.78 | 1.446128 | 2.53 | 0.1 | 1.49 | 2.512013 |
| Basic Shares Outstanding | 429.80M | 445.98M | 447.60M | 437.96M | 414.79M | 388.13M |
| Diluted Shares Outstanding | 429.80M | 445.98M | 447.60M | 437.96M | 414.79M | 388.13M |
| Ebit | 1.63B | 1.55B | 1.88B | 418.02M | 1.40B | 1.85B |
| Ebitda | 1.61B | 1.36B | 1.57B | 983.16M | 1.48B | 1.72B |
| Net Income Continuous Operations | 1.32B | 1.33B | 1.70B | 230.06M | 1.24B | 1.70B |
| Minority Interests | -553.24M | -471.83M | -565.25M | -187.23M | -621.47M | -726.91M |
| Preferred Stock Dividends | - | - | -392.72M | - | - | 479.84M |
The information on this page is provided for general informational purposes only and is not investment advice.
Market data provided by Twelve Data. Charting by TradingView.
Last updated:
